EXPLORE THE SCIENCE
TL;DR: A 2026 Phase 2 trial in The British Journal of Psychiatry found that 10 mg emestedastat did not improve attention and working memory after six weeks in adults with major depressive disorder and objectively measured cognitive impairment. A nominal depres…
Read article
TL;DR: A 2026 longitudinal study in Journal of Korean Medical Science found that self-reported phobic anxiety on the Symptom Checklist-90-Revised helped predict 2-month depression treatment response even when baseline clinician-rated depression and anxiety sco…
Read article
TL;DR: A 2026 study in Translational Psychiatry found that ketamine changed EEG-derived high-order brain interactions in late-life treatment-resistant depression, and a 24-hour increase in alpha-band redundancy tracked greater depression improvement by Day 7.…
Read article
TL;DR: A 2026 study in The British Journal of Psychiatry found that 4 weeks of twice-weekly subcutaneous racemic ketamine helped a minority of people with treatment-resistant depression, but response fell from 30% at treatment end to 17% 4 weeks later. Key Fin…
Read article
TL;DR: A 2026 randomized trial posted to medRxiv found that connectivity-guided accelerated intermittent theta-burst stimulation added to inpatient care improved treatment-resistant depression scores more than sham stimulation over 2 weeks. Key Findings 57 ran…
Read article